Born 1 February, 1955. He obtained his undergraduate degree in Pharmacology from the University of Bristol, UK in 1977 and a PhD from the School of Pharmacy (now UCL) in London, UK in 1980. He was a postdoctoral fellow in the Department of Physiology at the University of British Columbia (Vancouver, Canada) and in the Department of Physiology and Pharmacology at the University of New South Wales (Sydney, Australia). In 1983 he was appointed to a lectureship at the Department of Pharmacology at the University of Bristol. From 1990 until 1994 he was the Departmental Chair in Pharmacology at the University of Birmingham (UK). In 1994 he returned to the University of Bristol as the Professor of Neuroscience in Anatomy. There he served as Departmental Chair of Anatomy (1997-1999) and then as the Director of the MRC Centre for Synaptic Plasticity (1999-2012).
Professor Collingridge has held visiting Professorships at the University of British Columbia and at Seoul National University. He served as Editor-in-Chief of Neuropharmacology from 1993 until 2010. In 1997 he was elected a Founder Fellow of the European DANA Alliance; and in 1998 he was elected a Founder Fellow of the Academy of Medical Sciences (UK). In 2001 he was elected a Fellow of The Royal Society, and from 2007 until 2009 he served as President of the British Neuroscience Association (BNA). He is currently the reviews editor for Molecular Brain and serves on the scientific advisory board of Hello Bio.
Graham Collingridge is the Ernest B. and Leonard B. Smith Professor and Chair of the Department of Physiology at the University of Toronto. He is also a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital in Toronto. Professor Collingridge also holds an appointment in the School of Physiology, Pharmacology and Neuroscience at the University of Bristol, UK.
Honors and awards
Professor Collingridge’s research focuses on the mechanisms of synaptic plasticity in health and disease, in particular, understanding synaptic plasticity in molecular terms and how pathological alterations in these processes may lead to major brain disorders, such as Alzheimer’s disease.